Monopar Therapeutics CEO Robinson sells $2.5m in stock

Chandler Robinson, CEO and Director of Monopar Therapeutics (MNPR), sold $2.5 million worth of the company's stock on September 24, 2026, according to a SEC filing. The sale comprised 29,056 shares, with prices per share ranging from $87.15 to $89.79. The transactions were conducted under a Rule 10b5-1 trading plan Robinson established on June 25, 2026.

Currently, the stock price stands at $83.72, down 13% in the past week but up 55% over the past six months. Analysts believe the stock is overvalued, with price targets ranging from $119 to $145. Simultaneously, Robinson purchased 29,056 shares of Monopar Therapeutics stock through the exercise of stock options, valued at approximately $631,680.

This brought his direct ownership to 99,267 shares, with an additional 62,815 shares held indirectly via trust. Monopar Therapeutics has been busy with significant developments, including a rolling New Drug Application submission for ALXN1840, a Wilson disease treatment, and the appointment of three new commercial executives. However, Cantor Fitzgerald downgraded the stock to Neutral from Overweight despite raising the price target to $119.

BTIG and H.C. Wainwright have also increased their price targets to $133 and $125, respectively, maintaining Buy ratings. Analysts cite the NDA filing and potential future earnings as key factors.